1. Pink Sheet

Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen

 
• By Shirley Haley

Ranbaxy is partnered with another Indian drug maker, Zenotech, in its foray into biosimilar development.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet